• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Small Innovators & Niche CROs

    Focus on Science

    Rapid and Data Rich Chromatographic Method Development

    Preparing Your Post Pandemic Talent Strategy

    How Modern Near-Infrared Came to Be
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Waters and Genovis Enter Biopharmaceutical Partnership

    Frontage Acquires Ocean Ridge Biosciences

    AGC Biologics Expands Partnership with Rocket Pharmaceuticals

    TraceLink Introduces Opus Platform

    Evotec to Build Second Biologics Mfg. Facility in Toulouse
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Evotec to Build Second Biologics Mfg. Facility in Toulouse

    Abenza Chooses North Carolina for New Biologics Manufacturing Site

    Catalent Adds Cryogenic Capabilities at Philadelphia Facility

    Recro, Ensysce Expand Development and Manufacturing Partnership

    Metrics Names Stephanie Emory Associate Director of Pharma Development
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    TraceLink Introduces Opus Platform

    Obituary Notice: Russell “Russ” Haines

    Catalent Adds Cryogenic Capabilities at Philadelphia Facility

    Cryoport Acquires Critical Transport Solutions Australia

    PharmParts – This Makes Sense!
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Decentralized Clinical Trials: The 101 on Digital Health Technologies (DHTs)

    Lessons Learned: Choosing and Managing a CDMO

    Waters and Genovis Enter Biopharmaceutical Partnership

    AGC Biologics Expands Partnership with Rocket Pharmaceuticals

    TraceLink Introduces Opus Platform
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Ensuring Pharma Manufacturing Quality

    What Will Change at FDA for 2021?

    RBQM Comes of Age: COVID as a Catalyst for Change

    Post-Pandemic Regulations

    Enteris BioPharma: Custom Solutions – From Bench to Market
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Syngene

    Alcami

    Emergent BioSolutions

    Aphena Pharma Solutions

    Reed-Lane
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Almac Group

    Syngene

    Quotient Sciences

    PCI Pharma Services

    Emergent BioSolutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Pharma Year 2017 in Review

    CDMOs grow faster than the Pharma market.

    Pharma Year 2017 in Review
    Pharma Year 2017 in Review
    Pharma Year 2017 in Review
    Pharma Year 2017 in Review
    Pharma Year 2017 in Review
    Pharma Year 2017 in Review
    Pharma Year 2017 in Review
    Related CONTENT
    • Exploring ICP-MS expertise at Almac
    • The Ever-Evolving World of Combination Products
    • Outsourcing Solid Dosage Manufacturing
    • Vetter Establishes Office in China
    • Oakwood Labs
    Christoph Bieri, Managing Partner, Kurmann Partners03.09.18
    Globally, deal activity in 2017 was at a comparable level to 2016, and significantly lower than in 2014 and 2015. We counted 323 transactions (2016: 345), with cumulative deal values of $120 billion (2016: $95bn). In comparison, in 2014 and 2015, there were 440 to 490 transactions with cumulative deal values of approximately $225 billion. We believe that the earlier years were exceptional, and that the 2016/2017 level likely reflects normal rather than subdued merger and acquisition (M&A) activity.

    While global transaction numbers remained stable, the pattern shifted. As shown in Figure 1 in the picture slides above, there were fewer acquisitions involving targets based in the U.S., but significantly greater activity from bidders in emerging markets, when compared to 2016.

    The end of a long courtship for Actelion
    The largest transaction in 2017 was J&J’s acquisition of Actelion for $30 billion (see Figure 2 in the slide), the Swiss-based specialist in pulmonary arterial hypertension (PAH), and Europe’s largest biotech company.

    Back in 2011, activist investor Eliott tried to push Actelion’s management to initiate a sale process, when the company was trading at around 45 CHF per share. In January 2017, after a long and very public courtship in the second half of 2016—with Sanofi stepping in and out of the process—J&J agreed to pay CHF 280 per share.

    The valuation is perceived as very high, corresponding to 12 times revenues and 30 times EBIT. But not only did Actelion’s founders, Jean-Paul and Martine Clozel, realize a very attractive price for their shareholders, they also managed to carve-out Actelion’s pipeline and R&D outside the PAH franchise indication into a new company, Idorsia. In June 2017, the new company was floated on the Swiss stock exchange, and at the end of 2017 already had a market capitalization of more than $3 billion.

    Without doubt, Actelion is one of the most successful biotech stories in Europe to date.

    Big bets on cancer
    A substantial amount of available M&A funds in the pharma industry is spent on so-called “pipeline deals,” when large Pharma companies acquire small innovators with development programs or innovative products. The substantial prices paid in these transactions are based on the expectation of future profits which quite often are elusive; the deals are veritable billion-dollar bets.

    And Pharma is betting on oncology. Gilead acquired Kite Pharma for $10 billion, just before the latter’s CAR-T cell therapy against a form of B-cell cancer was approved. In January, Takeda paid $5 billion for Ariad Pharmaceuticals to get Ariad’s blood cancer drug and its lung cancer drug candidate. In December, Novartis offered $3.7 billion to secure the rights for AAA’s endocrine cancer treatment. And just before the year-end, Roche purchased Ignyta for $1.8 billion to take on a program of drug candidates against specific solid tumors.

    Continuing consolidation among CMOs and CROs
    Interestingly, five of the transactions with deal values greater than $1 billion involved companies which provide services to the Pharma industry, rather than Pharma companies themselves.

    In the contract manufacturing organization (CMO) space, former serial acquirer Patheon was taken over by ThermoFisher, the provider of R&D technology and Pharma services, for $7 billion. In the same period, Lonza completed the acquisition of Capsugel (announced in 2016, not in Figure 2) for $5.5 billion.

    In 2016, the merger of IMS Health and Quintiles (now trading as IQVIA) created a company providing services from early-stage research through to commercialization. In 2017, INC and InVentiv Health followed suit in a merger valued around $4.6 billion, with the stated claim to become another “end-to-end” service provider for the industry.

    Private equity groups (PEGs) drove the shaping of the CMO and the contract research organization (CRO) industries. PEGs seem to have continued confidence in the sector, increasing the value of the single bets. The CROs PPD and Parexel and the CDMO AMRI were acquired in billion-dollar transactions, a clear sign that financial investors believe that more consolidation is coming, and that operational improvements can be achieved.

    Renewed deal activity in generics
    Three transactions announced in 2017 with deal values greater than $1 billion involved generic drug firms. Akorn was acquired for $4.8 billion by Fresenius Kabi. With the deal, Fresenius expanded its portfolio of generics from sterile injectables to other difficult-to-make formulations. The other large deal in the U.S. was Amneal’s acquisition of IMPAX, a deal which was seen as a defensive step to the evolving crisis in the generics market in the U.S.

    In Europe, STADA, one of Europe’s largest generic drugs providers, was bought out by a consortium of investors for $6 billion. The protracted and highly public transaction process involved some drama, including the involuntary departure of the CEO and CFO of STADA, and the alleged installation of electronic surveillance equipment in the car of the CEO.

    More deals expected after tax overhaul
    The end of 2017 brought a big tax overhaul in the U.S., and many financial advisors expect that this may lead to increased M&A activity involving U.S. companies as buyers, across all industries.

    Against this backdrop, some observers expect that large deals amongst originators may be on the rise in 2018, particularly as pipeline deals become scarcer. Both Novartis and Sanofi are said to be under pressure to do large acquisitions. BMS is perceived as a potential target, and AstraZeneca’s survival as an independent company is often questioned.

    Large deals building momentum in OTC
    In OTC, three large transactions seem to be building momentum: In October, Merck KGaA announced the intention to sell its OTC portfolio business, with revenues of €860 million, which is expected to fetch €1.8 billion to €2.7 billion. This divestment was expected since February, as the German company then announced the preparation of the organization for a separation.

    Shortly after Merck’s announcement, Pfizer announced that they are seeking a buyer for their consumer health business. With revenues of $3.4 billion and a purchase price of up to $15 billion, Pfizer’s proposed deal is much larger.

    There are few obvious buyers for the portfolios. In March, GSK will have to decide whether to buy out Novartis from their JV. Bayer is still digesting its huge acquisition of OTC products from Merck & Co, and Reckitt Benckiser—keen to expand its OTC business—may first have to do a lot of homework.

    CDMOs grow faster than the Pharma market
    As Pharma companies refine their business strategy and market focus, Pharma manufacturing also undergoes a fundamental change. More and more, large Pharma “originators” view manufacturing as a non-core activity, unless the products involve proprietary technology. This is a boost for contract development and manufacturing organizations (CDMOs), and one of the key drivers for the consolidation of this industry.

    CDMOs collectively generate approximately $40 billion in revenue, and the large players forecast a market growth of 5% to 6.5% per year over the next five years. Two growth drivers are stated: First, small innovators (“biotech”) do not want to commit capital to building manufacturing plants, but rather use CDMOs. Second, outsourcing by Big Pharma is expected to increase further, from an “outsourcing penetration” of 30% today to 40% in 2020. Following this rationale, we believe that the CDMO industry may expand even faster, given that growth of the Pharma industry as a whole is expected to be 5% to 7%.

    Interestingly, the largest CDMOs grow faster than the largest Pharma firms, as can be seen in Figure 3 in the slider. Each bubble in this graph represents one company, with its size proportional to the company’s revenues. The position on the horizontal axis reflects the company’s growth in the last three years, while the position on the vertical axis reflects the profitability (EBITDA margin). The higher rate of growth of CDMOs reflects on one hand the consolidation in the CDMO market, and on the other hand the growing trend towards outsourcing in the industry. For comparison, Figure 3 also contains some of the large CROs, which also grew substantially faster than the Pharma market.

    Big Pharma’s bias for large CDMOs drives consolidation
    Despite a considerable number of M&A transactions, the CDMO market remains very fragmented. The top five players generate approximately 15% of the $40 billion total, and there is a long tail of medium-sized and smaller CDMOs—we count at least 300 companies offering CDMO services.

    However, there is a strong bias by Big Pharma for large CDMOs: Big Pharma firms want few, long-term, reliable relationships, and favor large CDMOs, which also have the capacity and means to manage and cultivate complex niche technologies, over smaller ones. A similar “size affinity” exists between Pharma companies and CROs. 

    Consequently, the CDMO industry is in a phase of intense consolidation, comparable to the CRO industry three to five years ago. As shown in Figure 4 in the slider, between 2013 and 2017 there were 30 to 60 transactions annually with C(D)MOs and manufacturing units as targets. The number of transactions peaked in 2015, but while the number of transactions decreased in the last two years, the deal volume (the sum of all published deal values) increased, mainly due to the very large deals: Capsugel/Lonza and Patheon/Thermo Fisher.

    Platform builders and new entrants
    Two particular type of M&A actors drive deal activity. First, several CDMOs made serial acquisitions to expand their platform and reach. Figure 5 in the slider illustrates the acquisition timeline of Catalent, Recipharm and Patheon which have used M&A to build up sizeable manufacturing platforms. These players use M&A as part of their business model to complement their technology footprint, geographic reach, and client portfolio.

    Second, new entrants, attracted to the industry consolidation, being driven by fragmentation, growth and size bias. As mentioned above, private equity groups (PEGS) have played a strong role in building the CDMO industry—as well as for CROs—and last year again saw several transactions involving PEGs buying out CDMOs, most notably AMRI. In addition, firms in related industries such as Thermo Fisher, a lab instrument and consumables supplier, are attracted to the CDMO industry. Table 1 in the slider deck gives examples of recent acquisitions of CDMOs by strategic buyers and private equity groups.

    Biopharma contract manufacturing
    Manufacturing of biologicals, for example antibodies which are produced using very sensitive mammalian cell cultures, is highly complicated and requires large dedicated investments. Even some of the largest Pharma companies prefer to enter into strategic alliances with specialist CDMOs, rather than building manufacturing plants on their own, as exemplified by Sanofi’s €270 million alliance with Lonza announced in February 2017.

    Due to the high barriers to entry, the biopharmaceutical CMO market is an oligopoly in which Samsung Biologics, Lonza and Boehringer have the lion’s share. However, some large new players are seeking to muscle their way in: Japanese Asahi Glass acquired CMC Biologics at the end of 2016, and KBI, subsidiary of Japanese group JSR, acquired two companies to expand its biopharmaceutical contract manufacturing capabilities.

    Biopharmaceutical toll manufacturing and biosimilar development overlap, as the example of Samsung Biologics shows. This company offers contract manufacturing services and has developed several biosimilars, in partnership with large biotech companies. Samsung Biologics is also an example of a successful new entrant into the CDMO market—with anticipated volume of 362,000 liters for mammalian cell culture, it is currently the largest biopharmaceutical CDMO. The company went public in November 2016 and at the beginning of 2018 traded at a market capitalization of more than $24 billion.

    The beginning of Pharma-CMO alliances?
    Pharma companies have for many years been relying on the acquisition of, or in-licensing from, biotech companies for innovation. In 2011 McKinsey, a consultancy, suggested that like the automotive industry, other parts of the Pharma value chain may disintegrate, with few large brand-owners sourcing everything—from innovation to manufacturing—through a network of suppliers. Along these lines, in the first half of this decade, Big Pharma companies have entered into strategic alliances with CROs, establishing preferred relationships with few (two or three) CROs instead of deciding case by case (or trial by trial) with whom to work.

    The same may happen in manufacturing. The large CDMOs are big, stable, and broad enough to cover substantially all manufacturing needs of Big Pharma companies, perhaps apart from biopharmaceuticals which may be covered by specialist CDMOs. We believe this is one reason for Lonza’s acquisition of Capsugel—complementing existing technical capabilities and gaining scale. Similarly, Patheon becomes part of a large group under Thermo Fisher and hence may be viewed as an even more compelling potential partner for Big Pharma companies.

    Obviously, given the many technical and regulatory constraints, transformation of a manufacturing network takes much more time to implement than changing suppliers of services. However, the transfer of manufacturing units from Pharma company to its future CDMO, could accelerate the process—thus the future of the CDMO industry may resemble its beginnings in the mid-90s. 


    Christoph Bieri is managing partner with Kurmann Partners, a Swiss-based M&A boutique focused on mid-market transactions in the pharmaceutical and medtech industries and adjacent segments. Christoph has led numerous buy-side and sell-side international transac-tions concerning targets based in the Europe and North America.
    Related Searches
    • Contract Research
    • CMO
    • biotech
    • equipment
    Suggested For You
    Exploring ICP-MS expertise at Almac Exploring ICP-MS expertise at Almac
    The Ever-Evolving World of Combination Products The Ever-Evolving World of Combination Products
    Outsourcing Solid Dosage Manufacturing Outsourcing Solid Dosage Manufacturing
    Vetter Establishes Office in China Vetter Establishes Office in China
    Oakwood Labs Oakwood Labs
    Delivering Custom Client Solutions Delivering Custom Client Solutions
    Navigating Uncertainty: Considerations for Life Sciences 2021 Navigating Uncertainty: Considerations for Life Sciences 2021
    Reed-Lane Adds Second Track & Trace Cartoning Line Reed-Lane Adds Second Track & Trace Cartoning Line
    Samsung Biologics Samsung Biologics
    Cell & Gene Therapy Supply Chain: Early Preparation is Key Cell & Gene Therapy Supply Chain: Early Preparation is Key
    Inspecting the Unexpected Inspecting the Unexpected
    The Pandemic & The Pharma Industry: 3 Things to Know The Pandemic & The Pharma Industry: 3 Things to Know
    Preparing to Adopt Intelligent Label Management Preparing to Adopt Intelligent Label Management
    Taros Chemicals Taros Chemicals
    Rising to The Occasion: The High Stakes of Vaccine Transport Rising to The Occasion: The High Stakes of Vaccine Transport

    Related Features

    • R&D
      Small Innovators & Niche CROs

      Small Innovators & Niche CROs

      Smaller CROs have the opportunity to provide a niche approach to its clients, particularly smaller sponsors who have shared synergies.
      Neil Goodman, David Bruce and Mohamed El Malt, Europital 04.01.21

    • Laboratory Testing
      Focus on Science

      Focus on Science

      How to maximize lab performance and value through comprehensive equipment management.
      Rohit Shroff, Senior Vice President, Global Lab Products, Avantor 04.01.21

    • Analytical Services | Bioanalytical Services | Laboratory Testing | R&D
      Rapid and Data Rich Chromatographic Method Development

      Rapid and Data Rich Chromatographic Method Development

      An overview of what to consider when developing chromatographic methods.
      Daniel Kirschner, Executive Director of Analytical Services, Cambrex - Durham, North Carolina 04.01.21


    • Preparing Your Post Pandemic Talent Strategy

      Preparing Your Post Pandemic Talent Strategy

      Areas for consideration for adopting the right approach to reinforce investments, optimize business and maximize your workforce.
      Neil Kelly, Managing Partner, Vector Partners 04.01.21

    • Laboratory Testing | R&D
      How Modern Near-Infrared Came to Be

      How Modern Near-Infrared Came to Be

      First region outside the visible to be discovered and last to be utilized.
      Gary E. Ritchie, Contributing Writer 04.01.21

    • APIs | Supply Chain
      Securing Your API Supply Chain: Three Keys to Success

      Securing Your API Supply Chain: Three Keys to Success

      Key considerations when outsourcing API procurement and supply chain management.
      Selwyn Lustman and Lina Cogan, LGM Pharma 04.01.21


    • Solid Dosage/Semi-solids
      Hygienic Packaging Technology

      Hygienic Packaging Technology

      Growing consumer demand for health products highlights hygienic packaging.
      John Brown, Vice President of Global Marketing, Selig 03.01.21

    • Drug Delivery | Solid Dosage/Creams/Ointments
      Trends in Solid Oral Dosage Delivery

      Trends in Solid Oral Dosage Delivery

      Capsule demand continues to rise due to this delivery system’s versatility.
      Anita Solanki, Milind Biyani and Jnanadeva Bhat, PhD , ACG Capsules 03.01.21

    • Information Technology
      5 Reasons Paper Has No Place in Contract Manufacturing

      5 Reasons Paper Has No Place in Contract Manufacturing

      Digital solutions create more efficient manufacturing processes and eliminate delays.
      Dave Edwards, Chief Revenue Officer, MasterControl 03.01.21


    • Drug Delivery | Parenterals
      Injectable Drug Delivery Trends

      Injectable Drug Delivery Trends

      How medication trends are driving the shift to patient-friendly drug delivery systems.
      Peter Soelkner, Managing Director, Vetter 03.01.21

    • Pharmaceutical Manufacturing  Equipment Trends

      Pharmaceutical Manufacturing Equipment Trends

      Demand for flexibility remains the driving force behind equipment systems.
      Kristin Brooks, Managing Editor, Contract Pharma 03.01.21

    • Drug Delivery | Solid Dosage/Creams/Ointments
      Oral Solids:   Market & Technology Trends

      Oral Solids: Market & Technology Trends

      Oral solids remain the preferred route of drug delivery due to their cost-effectiveness, ease of manufacturing, and patient-friendly dose form options.
      Tim Wright, Editor, Contract Pharma 03.01.21


    • Nutraceutical Manufacturing:  Meeting the Challenges of Today, Planning for  Tomorrow

      Nutraceutical Manufacturing: Meeting the Challenges of Today, Planning for Tomorrow

      Companies continue balancing high demand, supply disruption, and worker safety during the pandemic.
      Sean Moloughney, Editor, Nutraceuticals World 03.01.21

    • 2021 Contract  Manufacturing Survey

      2021 Contract Manufacturing Survey

      Our fourth annual audience poll indicates continued reliance on manufacturing partners, particularly for small businesses.
      Sean Moloughney, Editor, Nutraceuticals World 03.01.21

    • APIs
      Small Molecule Development Trends

      Small Molecule Development Trends

      A Q&A with Cambrex Edinburgh’s site director, Mark Benger.
      Tim Wright, Editor, Contract Pharma 03.01.21

    Trending
    • Pfizer, BioNTech Expand COVID-19 Vaccine Agreement With EU
    • Obituary Notice: Russell “Russ” Haines
    • Resilience Acquires Ology Bioservices
    • Johnson & Johnson 1Q Results
    • Sartorius Expands In The UK
    Breaking News
    • Waters and Genovis Enter Biopharmaceutical Partnership
    • Frontage Acquires Ocean Ridge Biosciences
    • AGC Biologics Expands Partnership with Rocket Pharmaceuticals
    • TraceLink Introduces Opus Platform
    • Evotec to Build Second Biologics Mfg. Facility in Toulouse
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Small Innovators & Niche CROs
    • Focus on Science
    • Rapid and Data Rich Chromatographic Method Development
    • Preparing Your Post Pandemic Talent Strategy
    • How Modern Near-Infrared Came to Be
    • Securing Your API Supply Chain: Three Keys to Success
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Innova Market Insights: Sports Nutrition Must Focus on Flavors for Mainstream Consumers
    Probiotic Strain Evidenced to Reduce Iron Deficiency/Anemia Risk
    Longvida Curcumin Extract Receives ANVISA Approval in Brazil
    Coatings World

    Latest Breaking News From Coatings World

    Keim-additec Hires Tyler John as Technical Sales Manager
    Nouryon Appoints Julie Aslaksen to Board of Directors
    RadTech Announces New Board Members, Secretary, Honorary Lifetime Member
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    J&J’s Veritas Vision System Receives FDA Clearance and CE Mark
    Viz.ai’s AI-Powered Platform Can Improve Outcomes for Stroke Patients
    FDA Breakthrough Device Designation Granted for pdSTIM System
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Waters and Genovis Enter Biopharmaceutical Partnership
    Frontage Acquires Ocean Ridge Biosciences
    AGC Biologics Expands Partnership with Rocket Pharmaceuticals
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    How Do Americans Feel About Diversity in Beauty Advertising?
    Estée Lauder Companies Reaffirms Sustainability Goals for Earth Month
    Coty’s Lancaster Earns C2C Certified Material Health Certificate
    Happi

    Latest Breaking News From Happi

    FDA Cites Disinfection Issues at Proposed Vaccine Production Site
    It's Official! L'Oréal Gets New CEO on May 1
    New Beauty Brand sk*p Wants to Break Addiction to Plastic
    Ink World

    Latest Breaking News From Ink World

    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    SE-DA Invests in Kornit Presto S
    Acrylic Resins Market Worth $21.9 Billion by 2025: MarketsandMarkets
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Global Graphics unveils new SmartDFE
    Channeled Resources installs new slitter in Toronto facility
    Kao Collins launches new website for printing inks and services
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    FiberVisions, Avgol Partner with Polymateria
    High-Tech Conversation Launches Wipes Dispenser
    Because Market Debuts Premium Plus Line
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Patients Conclude Clinical Visits in Knee Osteoarthritis Treatment Study
    SeaSpine Begins Limited Rollout of WaveForm TO 3D-Printed Interbodies
    Spinal Elements' Lucent 3D Additive Manufactured Interbodies Earn FDA Nod
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    SEMI Appoints imec, Soitec Executives to Europe Advisory Board
    TechBlick Announces Agenda For Next Printed, Hybrid, Structural, 3D Electronics Virtual Event
    NREL Takes Novel Approach to 3D-Printed Water Power Prototypes

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login